Marathon Capital Management
RPRX icon

Marathon Capital Management’s Royalty Pharma RPRX Stock Holding History

Marathon Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$547K Buy
9,371
+7
+0.1% +$413 0.11% 109
2026
Q2 		$525K Buy
9,364
+387
+4% +$20.1K 0.11% 106
2026
Q1 		$431K Buy
8,977
+1,379
+18% +$60.4K 0.1% 116
2025
Q4 		$294K Buy
7,598
+332
+5% +$12.7K 0.06% 133
2025
Q3 		$256K Buy
+7,266
New +$263K 0.06% 132

Other funds holding RPRX

Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $53.6B AUM 32.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Wedge Capital Management
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
Eastern Bank
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
Fideuram Asset Management (Ireland)
Fideuram Asset Management (Ireland) Dublin 1 $4.57B AUM 30.36% 1-Year Est. Return
Todd Asset Management
Todd Asset Management Louisville, Kentucky $5.51B AUM 33.77% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Marathon Capital Management's RPRX Position: Q3 2026 in Review

Marathon Capital Management increased its Royalty Pharma (RPRX) stake by 0.07% in Q3 2026, buying an estimated $413 and bringing the position to 9,371 shares worth $547K. The position accounts for 0.11% of the portfolio, ranked #109.

Marathon Capital Management first reported a position in RPRX in Q3 2025 and has held it in 5 quarters since. 186 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Marathon Capital Management held 9,371 shares of Royalty Pharma worth $547K as of Q3 2026.
  • Marathon Capital Management bought 7 Royalty Pharma shares in Q3 2026, an estimated $413.
  • Royalty Pharma made up 0.11% of Marathon Capital Management's portfolio in Q3 2026, its #109 holding.
  • Marathon Capital Management first reported a position in Royalty Pharma in Q3 2025 and has held it in 5 quarters since.
  • 186 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Marathon Capital Management's 13F filing for Q3 2026, filed 23 Oct 2026.